People don't take pills they can't feel working.
Inclisirán blocks PCSK9 protein production, enabling the body to eliminate LDL cholesterol more efficiently and reducing heart attack and stroke risk in vulnerable patients. The injection's twice-yearly dosing significantly improves treatment adherence compared to daily statins, which Brazilian patients typically abandon within 90 days despite needing year-long use for benefits.
- Inclisirán approved by Brazil's health regulator on June 19, 2023
- Reduces LDL cholesterol by 52% with two annual injections
- 92.6% of Brazilian heart attack survivors have unsafe LDL levels
- Patients typically abandon daily statins within 90 days
- Expected in Brazilian pharmacies within 90 days; pricing and SUS coverage undetermined
Brazil's health regulator approved inclisirán, a new injectable medication that reduces LDL cholesterol by 52% with just two annual doses, offering hope for high-risk cardiac patients who struggle with daily statin adherence.
Brazil's health regulator gave the green light on June 19 to a new injectable medication that could reshape how doctors treat patients at highest risk of heart attack and stroke. The drug, inclisirán, made by Novartis, works by blocking a protein called PCSK9 that normally breaks down the receptors responsible for pulling bad cholesterol from the bloodstream and shuttling it to the liver for disposal. When you stop that protein from doing its job, your body becomes far more efficient at clearing LDL cholesterol—the kind that hardens inside arteries and triggers cardiac events. Clinical trials showed that two injections per year reduce LDL levels by an average of 52 percent.
The numbers matter because they reveal a crisis hiding in plain sight. Among Brazilians who have already survived a heart attack, nearly 93 percent are still walking around with dangerously high LDL cholesterol. According to the American Stroke Association, one in four survivors of a clot-related stroke or heart attack will face another emergency. Cardiovascular disease kills more people in Brazil than any other cause, and globally the picture is the same. The problem is not that doctors lack tools—statins have been available for decades and can reduce cholesterol by about 26 percent on their own. The problem is that people stop taking them.
This is where inclisirán's design becomes significant. Statins require daily pills, and Brazilian patients typically abandon them within three months, even though the real benefits don't kick in until a year of consistent use. The reasons are straightforward: high cholesterol produces no symptoms. A person feels fine, so why keep swallowing a pill? The injection changes the equation. Administered under the skin in the abdomen, it requires just two doses annually after an initial year of four-month intervals. That simplicity could be the difference between a patient who stays the course and one who drifts away from treatment.
Cardiovascular specialists see genuine promise here. Raul Santos, a cardiologist at the University of São Paulo's Heart Institute and former president of the International Atherosclerosis Society, emphasizes that patients who have already suffered a cardiac event need to keep their LDL below 50 milligrams per deciliter—a target most fail to reach even with medication and lifestyle changes. Andrei Sposito, a cholesterol specialist at the State University of Campinas and member of the Brazilian Cardiology Society, points out that inclisirán solves two persistent problems: potency and adherence. It works better than statins, and the twice-yearly schedule means patients are far less likely to simply forget or give up.
The drug is already available in Europe and the United States, having won approval in 2020 and 2021 respectively. Brazilian pharmacies should stock it within roughly 90 days, though pricing remains undefined pending further regulatory review. Whether it will be covered by Brazil's public health system—the SUS—is an open question. Novartis has signaled interest in negotiating inclusion, but specialists expect the medication will be expensive given the technological sophistication required to develop it. Generic versions won't become possible until the patent expires in about a decade.
One caveat tempers the optimism: no studies yet confirm that inclisirán actually reduces the rate of heart attacks, strokes, or deaths from cardiovascular causes. The trials demonstrated that it powerfully lowers cholesterol, and the mechanism is sound, but the final proof—that fewer people die—remains to be gathered. Still, cardiologists are watching closely. The drug represents a different approach to a problem that has resisted solution through willpower and daily discipline alone. For patients at the highest risk, the ones who have already felt their hearts fail or their brains starved of blood, a treatment that asks for just two injections a year might finally be the intervention that sticks.
Notable Quotes
Patients who have already suffered a heart attack or stroke need to not just reduce cholesterol but control it, keeping it below 50 milligrams per deciliter.— Raul Santos, cardiologist at the University of São Paulo's Heart Institute
In Brazil, the average time patients use statins doesn't exceed 90 days. But we don't see benefits until a year, and they increase progressively over time.— Andrei Sposito, cholesterol specialist at the State University of Campinas
The Hearth Conversation Another angle on the story
Why does it matter that this injection only needs to happen twice a year instead of taking a pill every day?
Because people don't take pills they can't feel working. Cholesterol has no symptoms. A patient feels fine, so after a few months they think, why bother? But with an injection you get twice a year, you're forced back into the clinic. You can't forget it the same way.
So this is really a problem of human behavior, not just biology?
Exactly. The science of cholesterol management has been solved for decades. Statins work. But in Brazil, the average patient stops taking them after 90 days. The real problem is keeping people engaged in a treatment for something they can't feel.
What about the people who can't afford it?
That's the hard part. This drug will be expensive because of how it's made. For now it'll be in private pharmacies only. The public health system probably won't cover it for ten years, until generics become legal. So the people who need it most—the ones who've already had a heart attack and can't afford private care—won't have access.
But couldn't this drug eventually save money if it prevents heart attacks?
In theory, yes. One prevented heart attack pays for years of injections. But that argument only works if the drug actually prevents attacks, and we don't have that proof yet. We know it lowers cholesterol dramatically. We're betting the rest.
What's the biggest uncertainty here?
Whether lowering cholesterol this much actually translates to fewer deaths. The mechanism makes sense—less cholesterol in the blood means less buildup in arteries. But medicine is full of drugs that work perfectly in theory and disappoint in practice. We'll know in a few years.